AOD-9604 vs HGH Fragment 176-191: Comparing Two…

For laboratory and research use only. Not for human consumption.

AOD-9604 and HGH Fragment 176-191 are two of the most frequently confused compounds in the lipolytic-fragment peptide research space, largely because one is a direct structural derivative of the other. This article compares their origins, structural differences, and what published preclinical research has reported about each, so laboratory researchers can distinguish between the two when reviewing study designs or sourcing materials.

Key Facts

HGH Fragment 176-191 is the C-terminal fifteen-amino-acid fragment of the human growth hormone molecule.
AOD-9604 is a modified analog of HGH Fragment 176-191 with an added tyrosine residue at the N-terminus.
Both peptides were studied in early structure-function research as the region of growth hormone associated with lipolytic activity, separate from the region linked to growth-promoting activity.
AOD-9604's structural modification is reported in the literature to improve in-solution stability relative to the unmodified fragment.
Both compounds are supplied strictly for laboratory research and are not approved for human administration.

Origins: Isolating a Fragment of Human Growth Hormone

Human growth hormone is a 191-amino-acid protein with multiple functional domains studied over decades of endocrinology research. In the course of structure-function mapping, researchers identified that the C-terminal region — specifically amino acids 176 through 191 — appeared to be associated with lipolytic (fat-metabolism-related) activity in early cell and rodent studies, while lacking the activity linked to other regions of the hormone associated with skeletal growth signaling. This fragment was isolated and studied on its own as HGH Fragment 176-191, allowing researchers to investigate that specific region's activity independent of the rest of the hormone molecule.

AOD-9604: A Stabilized Derivative

AOD-9604 was developed as a modified version of HGH Fragment 176-191, incorporating an additional tyrosine residue and structural changes intended to improve the molecule's stability profile in solution and its resistance to enzymatic breakdown compared to the unmodified fragment. Because the underlying amino acid sequence overlaps substantially with HGH Fragment 176-191, much of the receptor-interaction research on AOD-9604 has been interpreted in light of the original fragment's characterized activity, with the modification treated as a stability and formulation improvement rather than a wholesale change in the peptide's studied mechanism.

What Preclinical Research Has Reported for Each Compound

Research on both HGH Fragment 176-191 and AOD-9604 has relied heavily on in vitro adipocyte (fat cell) assays and rodent models to characterize lipolytic activity — that is, effects on fat cell metabolism pathways measured within the model system. Published preclinical studies in this compound class have reported measured effects on markers of lipid metabolism in isolated adipocytes and in rodent models, alongside investigations into whether either fragment retains any of the growth-hormone-receptor-mediated activity associated with the full-length hormone. Across the published literature, researchers have generally reported that both fragments show minimal engagement with the growth-hormone-receptor pathways linked to skeletal growth signaling, which was the original rationale for isolating this region of the hormone in the first place.

Comparing Structural Stability

One of the most consistently studied differences between the two compounds is in-solution stability. Because AOD-9604 was specifically engineered with this in mind, laboratory comparisons have generally found it more resistant to degradation over time in aqueous solution than the unmodified HGH Fragment 176-191, a distinction that matters for researchers planning storage conditions and experimental timelines.

Comparing Structural Sequence

Both peptides share the same core fifteen-amino-acid backbone derived from the growth hormone sequence. The primary structural distinction is AOD-9604's additional N-terminal tyrosine residue, which researchers have studied as the modification responsible for the compound's altered stability characteristics relative to the parent fragment.

Choosing Between the Two for a Research Protocol

Because the two compounds are structurally related but not identical, researchers designing a study protocol should treat them as distinct variables rather than interchangeable materials, particularly when comparing results across different published studies. Readers building out a broader comparative picture of lipolytic-fragment and related growth-hormone-derived research peptides may also find our AOD-9604 vs. Tesamorelin research comparison useful, alongside our HGH Fragment 176-191 research overview, which reviews the fragment's isolation history and studied mechanisms in more depth. For laboratories preparing AOD-9604 for bench work, our AOD-9604 reconstitution lab protocol guide walks through concentration and solvent-volume calculations step by step.

Sourcing and Verification

Because both compounds are frequently sold under similar or overlapping branding, third-party verification is especially important. Researchers should confirm that any AOD-9604 or HGH Fragment 176-191 vial is accompanied by a lot-specific certificate of analysis showing both HPLC purity and mass spectrometry identity confirmation, which can be reviewed against the documentation standards outlined on our testing page.

Frequently Asked Questions

What is the structural relationship between AOD-9604 and HGH Fragment 176-191?

AOD-9604 is a modified analog of HGH Fragment 176-191, the C-terminal 15-amino-acid fragment of human growth hormone, with an added tyrosine residue and a stabilized structure designed to resist degradation in solution.

Why was HGH Fragment 176-191 originally isolated for research?

Researchers isolated HGH Fragment 176-191 because it corresponds to the region of the human growth hormone molecule associated with lipolytic activity in early structure-function studies, without the growth-promoting activity linked to other regions of the full hormone.

How do AOD-9604 and HGH Fragment 176-191 differ in stability?

AOD-9604's added stabilization is reported in the research literature to improve resistance to degradation in solution compared to the unmodified HGH Fragment 176-191, which is one of the main structural distinctions studied between the two peptides.

Are AOD-9604 and HGH Fragment 176-191 approved for human use?

No. Both peptides referenced here are sold and studied strictly as laboratory research compounds and are not approved by any regulatory agency for human administration.